DK3302437T4 - Stabile cannabinoidformuleringer - Google Patents
Stabile cannabinoidformuleringerInfo
- Publication number
- DK3302437T4 DK3302437T4 DK16800777.1T DK16800777T DK3302437T4 DK 3302437 T4 DK3302437 T4 DK 3302437T4 DK 16800777 T DK16800777 T DK 16800777T DK 3302437 T4 DK3302437 T4 DK 3302437T4
- Authority
- DK
- Denmark
- Prior art keywords
- cannabinoid formulations
- stable cannabinoid
- stable
- formulations
- cannabinoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Dispersion Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/724,351 US11224660B2 (en) | 2014-05-29 | 2015-05-28 | Stable cannabinoid formulations |
| US14/815,936 US11331279B2 (en) | 2014-05-29 | 2015-07-31 | Stable cannabinoid formulations |
| PCT/US2016/034565 WO2016191651A1 (en) | 2015-05-28 | 2016-05-27 | Stable cannabinoid formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3302437T3 DK3302437T3 (da) | 2023-01-09 |
| DK3302437T4 true DK3302437T4 (da) | 2026-02-23 |
Family
ID=57393689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16800777.1T DK3302437T4 (da) | 2015-05-28 | 2016-05-27 | Stabile cannabinoidformuleringer |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP4193990A1 (da) |
| JP (2) | JP6899506B2 (da) |
| AU (3) | AU2016267585C1 (da) |
| CA (1) | CA2986268C (da) |
| DK (1) | DK3302437T4 (da) |
| ES (1) | ES2938560T5 (da) |
| WO (1) | WO2016191651A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| US12544389B2 (en) | 2014-05-29 | 2026-02-10 | Fresh Cut Development, Llc | Stable cannabinoid formulations |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10059683B2 (en) | 2015-07-10 | 2018-08-28 | Noramco, Inc. | Process for the production of cannabidiol and delta-9-tetrahydrocannabinol |
| CA3062814C (en) * | 2017-04-27 | 2023-11-14 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| BR112019026877A2 (pt) | 2017-06-19 | 2020-06-30 | Zelda Therapeutics Operations Pty Ltd | composições para distúrbios do sono e tratamentos do mesmo |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| AU2018101357B4 (en) * | 2017-09-15 | 2022-03-17 | Zelira Therapeutics Operations Pty Ltd | Composition and method for treating autism |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| IL261132A (en) * | 2018-08-13 | 2018-11-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
| CN117695226A (zh) | 2018-12-11 | 2024-03-15 | 迪斯拉普申实验室公司 | 用于递送治疗剂的组合物及其使用方法和制备方法 |
| LU102486B1 (en) * | 2019-06-03 | 2021-06-15 | Fresh Cut Dev Llc | Cannabidiol nanocrystal compositions |
| US20220347118A1 (en) * | 2019-09-09 | 2022-11-03 | Cardiol Therapeutics Inc. | Stable medicinal cannabidiol compositions |
| US20220401380A1 (en) * | 2019-10-25 | 2022-12-22 | Cardiol Therapeutics Inc. | Cannabidiol compositions for use in treating heart conditions |
| GB201918846D0 (en) * | 2019-12-19 | 2020-02-05 | Gw Res Ltd | Oral cannabinoid formulations |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| JP2023527454A (ja) * | 2020-05-29 | 2023-06-28 | セレシン・インコーポレーテッド | 中鎖トリグリセリドを使用して点頭てんかんを処置する方法 |
| JP2023546649A (ja) * | 2020-09-24 | 2023-11-07 | ニコベンチャーズ トレーディング リミテッド | 製剤 |
| CA3201513A1 (en) * | 2020-12-07 | 2022-06-16 | Cardiol Therapeutics Inc. | Stable oral cannabidiol compositions |
| EP4274540A1 (en) * | 2021-01-11 | 2023-11-15 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Stable efficient cosmetic preparations |
| ES3032936T3 (en) * | 2021-04-12 | 2025-07-29 | Curantis Ug | Methods for optimizing treatment of mental disorders with cannabidiol and pharmaceutical compositions comprising cannabidiol |
| GB2617823A (en) * | 2022-04-11 | 2023-10-25 | Chanelle Mccoy Cbd Ltd | A cannabidiol oil and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117773A (en) * | 1996-04-02 | 2000-10-31 | Pharmos Ltd | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
| JP2001523221A (ja) * | 1996-09-01 | 2001-11-20 | ファーモス コーポレイション | 親油性物質の促進された生物学的利用能のための固形共沈物 |
| DK1361864T3 (da) * | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | Flyldende sprayformuleringer til bukkal indgivelse af cannabinoider |
| CH695661A5 (de) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
| EP1827393A4 (en) * | 2004-12-09 | 2012-04-18 | Insys Therapeutics Inc | AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS |
| US20140357708A1 (en) | 2005-11-07 | 2014-12-04 | Murty Pharmaceuticals, Inc. | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
| US20070104741A1 (en) * | 2005-11-07 | 2007-05-10 | Murty Pharmaceuticals, Inc. | Delivery of tetrahydrocannabinol |
| CA2760460C (en) * | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| EP2642982A2 (en) | 2010-11-22 | 2013-10-02 | Johnson Matthey Public Limited Company | Stable cannabinoid compositions and methods for making and storing them |
| US8741341B2 (en) * | 2012-05-07 | 2014-06-03 | Insys Therapeutics, Inc. | Manufacturing and packaging room temperature stable dronabinol capsules |
| DE102012105063C5 (de) | 2012-06-12 | 2023-09-14 | Thc Pharm Gmbh The Health Concept | Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen |
| US11331279B2 (en) * | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| EP4151234A1 (en) * | 2014-05-29 | 2023-03-22 | Fresh Cut Development, LLC | Stable cannabinoid formulations |
| CA3201513A1 (en) | 2020-12-07 | 2022-06-16 | Cardiol Therapeutics Inc. | Stable oral cannabidiol compositions |
-
2016
- 2016-05-27 CA CA2986268A patent/CA2986268C/en active Active
- 2016-05-27 EP EP22207141.7A patent/EP4193990A1/en active Pending
- 2016-05-27 ES ES16800777T patent/ES2938560T5/es active Active
- 2016-05-27 DK DK16800777.1T patent/DK3302437T4/da active
- 2016-05-27 WO PCT/US2016/034565 patent/WO2016191651A1/en not_active Ceased
- 2016-05-27 AU AU2016267585A patent/AU2016267585C1/en active Active
- 2016-05-27 JP JP2018513742A patent/JP6899506B2/ja active Active
- 2016-05-27 EP EP16800777.1A patent/EP3302437B2/en active Active
-
2021
- 2021-04-19 JP JP2021070161A patent/JP7374951B2/ja active Active
-
2022
- 2022-03-02 AU AU2022201441A patent/AU2022201441B2/en active Active
-
2024
- 2024-11-25 AU AU2024266845A patent/AU2024266845B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2986268A1 (en) | 2016-12-01 |
| ES2938560T5 (en) | 2026-04-24 |
| AU2024266845A1 (en) | 2024-12-12 |
| WO2016191651A1 (en) | 2016-12-01 |
| EP3302437B1 (en) | 2022-11-16 |
| EP3302437A4 (en) | 2018-12-05 |
| EP3302437B8 (en) | 2022-12-21 |
| JP6899506B2 (ja) | 2021-07-07 |
| AU2022201441B2 (en) | 2024-08-29 |
| AU2024266845B2 (en) | 2026-04-09 |
| AU2016267585A1 (en) | 2017-11-30 |
| EP3302437B2 (en) | 2025-12-24 |
| EP4193990A1 (en) | 2023-06-14 |
| ES2938560T3 (es) | 2023-04-12 |
| DK3302437T3 (da) | 2023-01-09 |
| EP3302437A1 (en) | 2018-04-11 |
| JP2021107438A (ja) | 2021-07-29 |
| CA2986268C (en) | 2024-01-02 |
| JP2018516281A (ja) | 2018-06-21 |
| AU2016267585C1 (en) | 2023-02-16 |
| AU2022201441A1 (en) | 2022-03-24 |
| JP7374951B2 (ja) | 2023-11-07 |
| AU2016267585B2 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289084A (en) | Cannabinoid formulations | |
| DK3302437T4 (da) | Stabile cannabinoidformuleringer | |
| EP3148589C0 (en) | STABLE CANNABINOID FORMULATIONS | |
| IL268697A (en) | Formulations | |
| DK3688162T3 (da) | Formuleringer | |
| EP3615079A4 (en) | STABLE CANNABINOID FORMULATIONS | |
| IL255028A0 (en) | Hydroponics | |
| PT3769781T (pt) | Formulação anti-ifnar1 estável | |
| MA50657A (fr) | Formulations de niraparib | |
| PL3368014T3 (pl) | Nowe preparaty kannabinoidów | |
| FR3039337B1 (fr) | Motoreducteur compact | |
| DK3163339T3 (da) | Polariseringsbevarende multikernefiber | |
| DK3226894T3 (da) | Stabile flydende vacciniavirus-formuleringer | |
| EP3367997A4 (en) | Novel occlusive formulations | |
| LT3386954T (lt) | Dimeriniai kontrastiniai agentai | |
| EP3462885A4 (en) | STABLE CANNABINOID FORMULATIONS | |
| EP3364945C0 (en) | SOLID FORMULATION | |
| EP3541200C0 (en) | POWDERED FORMULATIONS | |
| EP3383912A4 (en) | TOPICAL FORMULATIONS | |
| EP3308781A4 (en) | BLOOD PRESSURE CENTER | |
| HUE063178T2 (hu) | Kopanlizib formulációi | |
| EP3349766A4 (en) | ANTIHORMORRHAGIC COMPOSITIONS | |
| DE112016003293A5 (de) | Feuerlöscher | |
| IL272167A (en) | Hemopexin formulations | |
| DK3173071T4 (da) | Maropitantformulering |